Last update 19 Dec 2025

Conventional T Cell(Stanford University)

Overview

Basic Info

Drug Type
T-lymphocyte cell therapy
Synonyms-
Target-
Action-
Mechanism-
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases
Active Indication-
Inactive Indication
acute leukemiaAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+ [4]
Originator Organization
Stanford UniversityStanford University
Active Organization-
Inactive Organization
Stanford UniversityStanford University
License Organization-
Drug Highest PhasePendingPhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Conventional T Cell(Stanford University)
NCT01660607
/ CompletedPhase 1/2IIT
Phase 1-2 Trial for Patients With Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells
100 Clinical Results associated with Conventional T Cell(Stanford University)
Login to view more data
100 Translational Medicine associated with Conventional T Cell(Stanford University)
Login to view more data
100 Patents (Medical) associated with Conventional T Cell(Stanford University)
Login to view more data
100 Deals associated with Conventional T Cell(Stanford University)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
acute leukemiaPhase 2
United States
Stanford UniversityStanford University
09 Feb 2012
Acute Lymphoblastic LeukemiaPhase 2
United States
Stanford UniversityStanford University
09 Feb 2012
Acute Myeloid LeukemiaPhase 2
United States
Stanford UniversityStanford University
09 Feb 2012
Aggressive-Phase Chronic Myelocytic LeukemiaPhase 2
United States
Stanford UniversityStanford University
09 Feb 2012
Chronic phase chronic myeloid leukemiaPhase 2
United States
Stanford UniversityStanford University
09 Feb 2012
Myelodysplastic SyndromesPhase 2
United States
Stanford UniversityStanford University
09 Feb 2012
Non-Hodgkin LymphomaPhase 2
United States
Stanford UniversityStanford University
09 Feb 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free